FDA approves Sage's postpartum depression therapy

Sage gained FDA approval for Zulresso brexanolone Tuesday, making it the first drug specifically indicated to treat postpartum depression.

Sage Therapeutics Inc. (NASDAQ:SAGE) told BioCentury the average course of therapy will cost $34,000 per patient. Speaking to BioCentury ahead of the PDUFA date, CMO Steve Kanes said the company had planned to price the drug between $20,000-$35,000 per treatment cycle...